A Nose for OSD
Could a new nasal spray be a panacea for dry eye sufferers?
Elizabeth Yeu |
With an estimated 16 million adults suffering from dry eye disease (DED) in the US alone, there is huge appetite for more effective and easy-to-use therapeutic options. The news of the OC-01 nasal spray being released by Oyster Point Pharma was welcome news to me, as I feel it will have a real impact on my patients’ outcomes. The spray promises to overcome a number of challenges in ocular surface disease (OSD) management, namely by offering both physicians and patients a unique delivery system.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine